Efficacy and safety of hemoglobin-polyethylene glycol conjugate (pyridoxalated polyethylene glycol hemoglobin) as an oxygen-carrying resuscitation fluid

Artif Organs. 1986 Dec;10(6):470-4. doi: 10.1111/j.1525-1594.1986.tb02606.x.

Abstract

The safety and efficacy of a conjugate of pyridoxalated hemoglobin and polyethylene glycol (pyridoxalated PEG hemoglobin) were evaluated after administration to rats. The LD50 (lethal dose for 50% survival of group) of pyridoxalated polyethylene glycol (PEG) hemoglobin was greater than 200 ml/kg. Any pro- or anticoagulation activity was not demonstrated in in vitro coagulation tests. One day after 70% exchange-transfusion with pyridoxalated PEG hemoglobin, slight elevations of the serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase, and blood urea nitrogen values, which were 101.7 +/- 22.6 IU/L, 33.3 +/- 7.2 IU/L, and 23.1 +/- 1.4 mg/dl, respectively, were observed. However, these values were in the normal range after 3 days. With greater than 90% exchange-transfusion, all rats exchange-transfused with pyridoxalated PEG hemoglobin survived for greater than 2 weeks in contrast to the death of all the rats exchange-transfused with stroma-free hemoglobin or albumin.

MeSH terms

  • Animals
  • Blood Coagulation Tests
  • Blood Substitutes*
  • Exchange Transfusion, Whole Blood
  • Hemoglobins*
  • Kidney Function Tests
  • Liver Function Tests
  • Male
  • Polyethylene Glycols*
  • Pyridoxal*
  • Rats
  • Rats, Inbred Strains
  • Resuscitation*

Substances

  • Blood Substitutes
  • Hemoglobins
  • Pyridoxal
  • Polyethylene Glycols